On Monday, Ofir initiated coverage of Urthecast with a Speculative Buy rating and a $3.00 one-year price target.
Urthecast recently signed a decade long agreement with Russian aerospace company RSC Energia to place two high-def cameras on the International Space Station. The company is an early entry into the Earth Observation market, a space Ofir says is already worth $2-billion and is set to double by 2020. Urthecast will provide the first-ever streaming HD video delivering live imagery of the planet. He says this opens the company up to business through what might be considered traditional channels, such as defense and government agencies, but also to “broader commercial” markets such as the news media, agriculture and environmental monitoring.
Vancouver-based Urthecast, which was founded in 2010, has already compiled an executive team comprised of senior space industry vets, about $40-million in funding, and letters of intent that will deliver a minimum of $19-million in annual revenue, notes Ofir. He points out that if fully penetrated and converted, the business from these seven distribution partners has the potential to deliver as much as $140-million in annual revenue.
The Clarus analyst says the earth observation business is characterized by its significant barriers to entry. DigitalGlobe (DGI-NYSE) currently holds about 60% of the markets, with a few smaller players sharing the rest. Urthecast’s solution, he says, should be instantly competitive as the company’s multi-frame capture technology will allow it to produce still images at best-in-class resolutions.
At press time, shares of Urthecast were down 2.5% to $1.95.
Beacon Securities analyst Russell Stanley reiterated his “Buy” rating and street-high $88.00 target on MDA Space (MDA Space Stock Quote,… [Read More]
National Bank Financial analyst Baltej Sidhu raised his target on Hammond Power Solutions (Hammond Power Solutions Stock Quote, Chart, News,… [Read More]
RBC senior economist Claire Fan says Canada’s September job losses were concentrated among younger workers and should not be overread.… [Read More]
Roth Capital Partners analyst Adam Walsh says a third controlled celiac disease dataset supporting IL-15 blockade increases the potential value… [Read More]
Beacon Securities analyst Russell Stanley raised his target on Firan Technology Group (Firan Technology Group Stock Quote, Chart, News, Analysts,… [Read More]
Research Capital Corporation analyst Greg McLeish maintained his “Buy” rating and $3.50 target on Cannara Biotech (Cannara Biotech Stock Quote,… [Read More]